Success Metrics

Clinical Success Rate
88.2%

Based on 15 completed trials

Completion Rate
88%(15/17)
Active Trials
1(5%)
Results Posted
33%(5 trials)
Terminated
2(11%)

Phase Distribution

Ph not_applicable
1
5%
Ph phase_1
1
5%
Ph phase_2
5
26%
Ph phase_3
11
58%
Ph phase_4
1
5%

Phase Distribution

1

Early Stage

5

Mid Stage

12

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
1(5.3%)
Phase 2Efficacy & side effects
5(26.3%)
Phase 3Large-scale testing
11(57.9%)
Phase 4Post-market surveillance
1(5.3%)
N/ANon-phased studies
1(5.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.2%

15 of 17 finished

Non-Completion Rate

11.8%

2 ended early

Currently Active

1

trials recruiting

Total Trials

19

all time

Status Distribution
Active(1)
Completed(15)
Terminated(2)
Other(1)

Detailed Status

Completed15
Terminated2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
1
Success Rate
88.2%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (5.3%)
Phase 25 (26.3%)
Phase 311 (57.9%)
Phase 41 (5.3%)
N/A1 (5.3%)

Trials by Status

unknown15%
completed1579%
recruiting15%
terminated211%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT07226089Phase 3

Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.

Recruiting
NCT06007417Phase 3

A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency

Unknown
NCT03831880Phase 3

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

Completed
NCT03874013Phase 3

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

Completed
NCT03309891Phase 2

Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency

Completed
NCT02770157Phase 3

Efficacy and Safety of DA-3002 in Short Children Borns SGA.

Completed
NCT02204163Phase 3

Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome

Completed
NCT02879747Phase 2

Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children

Completed
NCT01699308Phase 1

Growth Hormone and Brain Functioning After Traumatic Brain Injury

Completed
NCT01813630Phase 3

A Clinical Study to Assess the Efficacy and Safety of DA-3002

Completed
NCT02946606Phase 2

A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9

Completed
NCT01723748Not Applicable

Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects

Completed
NCT00396097Phase 3

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

Completed
NCT01822340Phase 2

Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients

Completed
NCT01397500Phase 2

Hormone Treatment in Growth Hormone and Testosterone Deficient Patients

Terminated
NCT00884000Phase 3

A Study of Zomacton in Children With Growth Hormone Deficiency

Completed
NCT00555009Phase 4

Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury

Terminated
NCT00174408Phase 3

Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age

Completed
NCT00420251Phase 3

Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19